| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
|
|
|
||||||||||
|
||||||||||||
The British Journal of Psychiatry 173: 203-208 (1998)
© 1998 The Royal College of Psychiatrists
R McAskill, S Mir and D Taylor
Maudsley Hospital, London.
BACKGROUND: Antidepressant therapy is not always effective and is slow to take effect. In theory, these shortfalls may be caused by induction of neuronal negative feedback via pre-synaptic 5-HTIA receptors. Pindolol, an antagonist at somatodentritic pre-synaptic 5-HTIA receptors has been investigated as a potential accelerator and augmentor of antidepressant response. METHOD: A Medline search was conducted in November 1997. RESULTS: Six open-label studies and six controlled studies were identified for review. CONCLUSIONS: Open-label studies strongly suggest that pindolol may accelerate and augment antidepressant response, but controlled studies do not wholly support these findings: only three of six studies clearly demonstrate benefit. Larger, well-designed, controlled trials are needed to determine definitively the effectiveness of pindolol in this context.
This article has been cited by other articles:
|
|
 |
|
  A. F. Schatzberg, A. J. Rush, B. A. Arnow, P. L. C. Banks, J. A. Blalock, F. E. Borian, R. Howland, D. N. Klein, J. H. Kocsis, S. G. Kornstein, et al. Chronic Depression: Medication (Nefazodone) or Psychotherapy (CBASP) Is Effective When the Other Is Not Arch Gen Psychiatry, May 1, 2005; 62(5): 513 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Anderson Drug treatment of depression: reflections on the evidence Advan. Psychiatr. Treat., January 1, 2003; 9(1): 11 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Page, J. F. Cryan, A. Sullivan, A. Dalvi, B. Saucy, D. R. Manning, and I. Lucki Behavioral and Neurochemical Effects of 5-{4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl}-benzofuran-2-carboxamide (EMD 68843): A Combined Selective Inhibitor of Serotonin Reuptake and 5-Hydroxytryptamine1A Receptor Partial Agonist J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1220 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Thase, A. J. Rush, R. H. Howland, S. G. Kornstein, J. H. Kocsis, A. J. Gelenberg, A. F. Schatzberg, L. M. Koran, M. B. Keller, J. M. Russell, et al. Double-blind Switch Study of Imipramine or Sertraline Treatment of Antidepressant-Resistant Chronic Depression Arch Gen Psychiatry, March 1, 2002; 59(3): 233 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Rabiner, Z. Bhagwagar, R. N. Gunn, P. A. Sargent, C. J. Bench, P. J. Cowen, and P. M. Grasby Pindolol Augmentation of Selective Serotonin Reuptake Inhibitors: PET Evidence That the Dose Used in Clinical Trials Is Too Low Am J Psychiatry, December 1, 2001; 158(12): 2080 - 2082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Harrison and A. Markou Serotonergic Manipulations Both Potentiate and Reduce Brain Stimulation Reward in Rats: Involvement of Serotonin-1A Receptors J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 316 - 325. [Abstract] [Full Text]
|
|
|
|
|
|
B. Leonard Clinical implications of mechanisms of action of antidepressants Advan. Psychiatr. Treat., May 1, 2000; 6(3): 178 - 186. [Full Text]
|
|
|
|
 |
|
 O. Spigset and B. Mårtensson Fortnightly review: Drug treatment of depression BMJ, May 1, 1999; 318(7192): 1188 - 1191. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
